Gut molecule research could help control glucose levels 29 January 2018 Most of us know that insulin plays an important role in removing excess glucose from the blood, but did you know it isn’t the only molecule involved in the process? Another molecule that plays a role is glucagon-like peptide-1 (GLP-1). Now Professor Marco Falasca and his team from Curtin University, with the support of Diabetes Australia, are investigating ways of increasing the amount of GLP-1 somebody produces and whether that can help control glucose levels. “We know GLP-1 is released in the gut when people eat. It has a key role to play in regulating blood glucose levels,” Professor Falasca said. “We also know that people with diabetes have a decreased ability to release GLP-1, so what we want to do it find a way of increasing the body’s production of the molecule. “Researchers have tried to produce drugs that mimic GLP-1 but they haven’t been too successful so we are trying a different approach. “There is a compound in the body, belonging to the lipid family, which stimulates the release and production of GLP-1. What we are trying to do is determine if this lipid, or molecules similar to it, can be used to stimulate the production of GLP-1. “Hopefully, if we are successful, this could lead to a new therapy for supporting people with diabetes.” If you are interested in helping Diabetes Australia support research like this you can find out more here.
Media releases 22 November 2023 Regional and remote Australians urged to get late flu vaccine People living with diabetes in rural and remote areas are being urged to get their flu shot now after low rates of flu vaccinations have put communities at risk across Australia this year. Continue Reading
News 17 August 2023 Update on Fiasp insulin Diabetes Australia have been consistently talking with both the Federal Government and Novo Nordisk about the need for a solution before 1 October 2023. Continue Reading
News 2 August 2023 Statement on Glucagen Hypokit supply Novo Nordisk has notified the Therapeutic Goods Administration that the Glucagen Hypokit is currently in a shortage that will last until 30 September 2023. Continue Reading